• Options for Tax Reform
• Robin Hood in Reverse: The Case against Taking Private Property for Economic Development
• Peer-to-Peer Networking and Digital Rights Management: How Market Tools Can Solve Copyright Problems
• Who Killed Telecom? Why the Official Story Is Wrong
• Medicare Prescription Drugs: Medical Necessity Meets Fiscal Insanity

In a new Cato Policy Analysis, Chris Edwards, Cato's director of tax policy studies, addresses the unnecessary complexity and inefficiency of the present income tax system and proposes an alternative that would have most Americans paying just 15 percent. This plan would create a simpler and more efficient tax code within the structure of today's system.

In a new Cato Policy Analysis, George Mason University law professor Ilya Somin argues that the Constitution bans the government from taking property simply to encourage economic development. Many state courts have read "public use" broadly to allow government to transfer property from one private owner to another owner who is expected to make a greater contribution to the local economy.

A new Cato Policy Analysis argues that digital rights management (DRM) and peer-to-peer networking technologies can work together to provide new content services and help alleviate many copyright concerns. Market operations such as DRM are preferable to government technology controls or mandatory compulsory licensing schemes.

A new Cato report debunks the "official" story behind the telecom industry's collapse. Telecom's demise has long been blamed on manipulative executives, but in "Who Killed Telecom? Why the Official Story Is Wrong," Cato senior fellow Lawrence Gasman argues that the FCC's "unbundling" policy was the real culprit.

In a new Cato Briefing Paper, Joseph Antos, health care and retirement policy scholar at the American Enterprise Institute, and Jagadeesh Gokhale, senior fellow at the Cato Institute, argue that the Medicare prescription drug benefit could cost twice as much as the 10-year, $720 billion White House estimate. The drug benefits cost projections have already jumped 86 percent in two years, and are likely to increase again when the program is fully enacted in 2006.